Improving early detection of lung cancer through DNA methylation analysis
Optimizing Ultrasensitive DNA methylation detection for lung cancer and other malignancies
This study is looking at new ways to find lung cancer earlier by checking for special changes in DNA found in blood samples, which could help doctors catch the disease sooner and manage it better for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10902047 on NIH RePORTER |
What this research studies
This research focuses on enhancing the detection of lung cancer by analyzing specific changes in DNA methylation patterns. It involves developing highly sensitive assays to identify cancer-specific DNA in blood samples, which could lead to earlier diagnosis and better management of the disease. The project includes a dedicated laboratory for optimizing these detection methods and implementing them in clinical settings, ensuring that the findings can be effectively used in patient care. By refining these techniques, the research aims to improve the accuracy and reliability of lung cancer screening.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for lung cancer, such as those with a history of smoking or with screen-detected pulmonary nodules.
Not a fit: Patients with benign lung conditions or those who do not have any risk factors for lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate detection of lung cancer, potentially improving patient outcomes.
How similar studies have performed: Previous studies have shown promising results in using DNA methylation detection for cancer diagnostics, indicating a potential for success in this approach.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Herman, James G. — University of Pittsburgh at Pittsburgh
- Study coordinator: Herman, James G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.